Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALV003 in well-controlled celiac disease
NCT01255696Phase 2Completed
- Sponsor
- Alvine Pharmaceuticals
- Start
- Nov 2010
- Primary completion
- May 2011
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in celiac disease comparing ALV003 with Placebo (2 arms). Primary endpoints: Intestinal mucosal morphology (Villus height to Crypt depth ratio) at 6 weeks and Tolerability of ALV003 at 6 weeks. Started Nov 2010; status: completed.
02
Drugs
latiglutenase
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT01255696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01255696.